Technology ID
TAB-2558
Induced Pluripotent Stem Cells Generated Using Lentivirus-based Reprogramming
E-Numbers
E-274-2012-0
Lead Inventor
Boehm, Manfred
Lead IC
NHLBI
Co-Inventors
Chen, Guibin
ICs
NHLBI
Applications
Therapeutics
Research Materials
Diagnostics
Development Status
- Prototype
- Pilot
- Early-stage
- In vitro data available
Five human induced pluripotent stem cells (iPSC) lines are generated using lentivirus-based reprogramming technology. These lines are pluripotent, meaning they have the potential to differentiate into all cells in the body, and theoretically can proliferate/self-renew indefinitely. The iPSC lines are: NC1 (derived from female's fibroblasts), NC2 (derived from female's fibroblasts ), NC3 (derived from male's HUVECS), NC4 (derived from male's fibroblasts) and NC5 (derived from female's fibroblasts). Further details of these cells are available upon request. NC1 uses a retrovirus delivery system incorporating the following vectors: pMIG-hKLF4, pMIG-hOCT4, pMIG-hSOX2, and MSCV h c-MYC IRES GFP. NC2-NC5 use the hSTEMCCA-loxP lentivirus delivery system (a gift from Dr. Gustavo Mostoslavsky). These cell lines will be useful for studies related to stem cell biology, understanding diseases, potential cell therapies, and small molecule screening.
Commercial Applications
The iPSCs of this technology are useful:
- to study the biology of stem cell development
- as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases
- to test different characterization and differentiation assays
Competitive Advantages
- These cells can serve as control cells and, thus, significantly reduce the cost of initiating many research projects.
- These cells can be a good source of control cells.
Licensing Contact: